Literature DB >> 30124786

Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study.

Jeff Hosry1, Georgios Angelidakis1, Ahmed Kaseb2, Ying Jiang1, Harrys A Torres1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30124786      PMCID： PMC6206115          DOI： 10.1093/cid/ciy387

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  9 in total

Review 1.  New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants.

Authors:  Laura Gatti; Giuliana Cassinelli; Nadia Zaffaroni; Cinzia Lanzi; Paola Perego
Journal:  Drug Resist Updat       Date:  2015-05-07       Impact factor: 18.500

2.  The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.

Authors:  Véronique Descamps; François Helle; Christophe Louandre; Elodie Martin; Etienne Brochot; Laure Izquierdo; Carole Fournier; Thomas W Hoffmann; Sandrine Castelain; Gilles Duverlie; Antoine Galmiche; Catherine François
Journal:  Antiviral Res       Date:  2015-03-28       Impact factor: 5.970

3.  Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.

Authors:  Jennifer Arrondeau; Olivier Mir; Pascaline Boudou-Rouquette; Romain Coriat; Stanislas Ropert; Guillaume Dumas; Manuel J Rodrigues; Benoit Rousseau; Benoit Blanchet; François Goldwasser
Journal:  Invest New Drugs       Date:  2011-10-29       Impact factor: 3.850

4.  Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.

Authors:  Harrys A Torres; Jeff Hosry; Parag Mahale; Minas P Economides; Ying Jiang; Anna S Lok
Journal:  Hepatology       Date:  2017-11-13       Impact factor: 17.425

5.  The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.

Authors:  R Cabrera; A R Limaye; P Horne; R Mills; C Soldevila-Pico; V Clark; G Morelli; R Firpi; D R Nelson
Journal:  Aliment Pharmacol Ther       Date:  2012-10-24       Impact factor: 8.171

Review 6.  Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.

Authors:  Stanleyson V Hato; Andrea Khong; I Jolanda M de Vries; W Joost Lesterhuis
Journal:  Clin Cancer Res       Date:  2014-06-01       Impact factor: 12.531

7.  Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus.

Authors:  Junichi Shindoh; Kiyoshi Hasegawa; Yutaka Matsuyama; Yosuke Inoue; Takeaki Ishizawa; Taku Aoki; Yoshihiro Sakamoto; Yasuhiko Sugawara; Masatoshi Makuuchi; Norihiro Kokudo
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

8.  Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria.

Authors:  Barbara H McGovern; Christopher E Birch; Melinda J Bowen; Laura L Reyor; Ellen H Nagami; Raymond T Chung; Arthur Y Kim
Journal:  Clin Infect Dis       Date:  2009-10-01       Impact factor: 9.079

9.  Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy.

Authors:  Parag Mahale; Sheeba K Thomas; Andreas Kyvernitakis; Harrys A Torres
Journal:  Open Forum Infect Dis       Date:  2015-12-28       Impact factor: 3.835
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.